Cargando…
Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021–February 2022, VISION Network: a retrospective cohort study
BACKGROUND: Understanding the usefulness of additional COVID-19 vaccine doses—particularly given varying disease incidence—is needed to support public health policy. We characterize the benefits of COVID-19 booster doses using number needed to vaccinate (NNV) to prevent one COVID-19-associated hospi...
Autores principales: | Adams, Katherine, Riddles, John J., Rowley, Elizabeth A.K., Grannis, Shaun J., Gaglani, Manjusha, Fireman, Bruce, Hartmann, Emily, Naleway, Allison L., Stenehjem, Edward, Hughes, Alexandria, Dalton, Alexandra F., Natarajan, Karthik, Dascomb, Kristin, Raiyani, Chandni, Irving, Stephanie A., Sloan-Aagard, Chantel, Kharbanda, Anupam B., DeSilva, Malini B., Dixon, Brian E., Ong, Toan C., Keller, Jean, Dickerson, Monica, Grisel, Nancy, Murthy, Kempapura, Nanez, Juan, Fadel, William F., Ball, Sarah W., Patel, Palak, Arndorfer, Julie, Mamawala, Mufaddal, Valvi, Nimish R., Dunne, Margaret M., Griggs, Eric P., Embi, Peter J., Thompson, Mark G., Link-Gelles, Ruth, Tenforde, Mark W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266334/ https://www.ncbi.nlm.nih.gov/pubmed/37333688 http://dx.doi.org/10.1016/j.lana.2023.100530 |
Ejemplares similares
-
Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods
por: Link-Gelles, Ruth, et al.
Publicado: (2023) -
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022
por: Britton, Amadea, et al.
Publicado: (2022) -
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022
por: Link-Gelles, Ruth, et al.
Publicado: (2022) -
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
por: Ferdinands, Jill M, et al.
Publicado: (2022) -
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023
por: Link-Gelles, Ruth, et al.
Publicado: (2023)